BVT Put 95 NOVN 21.06.2024/ DE000VD49EM9 /
2024-06-18 7:53:37 PM | Chg.+0.033 | Bid9:59:18 PM | Ask9:53:42 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.215EUR | +18.13% | - Bid Size: - |
- Ask Size: - |
NOVARTIS N | 95.00 CHF | 2024-06-21 | Put |
GlobeNewswire
06-18
Erasca Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib in Patients...
GlobeNewswire
06-18
NMD Pharma Receives IND Clearance from the FDA to initiate a Phase 2 Clinical Trial of NMD670 in Cha...
GlobeNewswire
06-18
NMD Pharma Receives IND Clearance from the FDA to initiate a Phase 2 Clinical Trial of NMD670 in Cha...
GlobeNewswire
06-13
Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment
GlobeNewswire
04-16
Novartis’ Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthriti...
GlobeNewswire
03-14
IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon
GlobeNewswire
02-28
Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
GlobeNewswire
01-10
Novartis' Cosentyx Shows Promising Early Progress in Treating Hidradenitis Suppurativa, Poised for S...
GlobeNewswire
01-05
Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand ...
GlobeNewswire
01-02
Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Ad...
GlobeNewswire
2023-12-21
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
2023-12-19
Related Sciences Adds 8 New Senior Advisors Including Former CEOs and Heads of R&D from Genentech, N...
GlobeNewswire
2023-12-11
Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and ...
GlobeNewswire
2023-12-08
Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broa...